Editorial: Lipid metabolism in metabolic dysfunction- associated steatotic liver disease

Editorial: Lipid metabolism in metabolic dysfunction- associated steatotic liver disease

Saved in:

Bibliographic Details
Main Authors:	Sheetalnath Rooge, Nirajan Shrestha
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Medicine
Subjects:	MASLD lipid metabolism liver fibrosis free FA (FFA) MASH obesity
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1584932/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of Pemafibrate, a Selective Peroxisome Proliferator-activated Receptor ? Modulator (SPPARM?), on the Lipid Profile, Liver Function, and Liver Fibrosis among Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
by: Mona Hassan, et al.
Published: (2025-06-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes
by: Ankita Dua, et al.
Published: (2025-08-01)

The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease
by: Yu Zhang, et al.
Published: (2025-03-01)

Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease
by: Buket Yigit, et al.
Published: (2025-07-01)

Consensus Statement on Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL‐TSPGHAN Expert Committee
by: Yu‐Cheng Lin, et al.
Published: (2025-06-01)

The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Pieralice S, et al.
Published: (2025-07-01)

Serum Mac-2 binding protein glycosylation isomer as a biomarker for metabolic dysfunction associated steatotic liver disease
by: Ahmed M. F. Mansour, et al.
Published: (2025-05-01)

Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
by: Clara Meda, et al.
Published: (2025-01-01)

Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study
by: Yueqiu Wang, et al.
Published: (2025-12-01)

β-Resorcylic acid prevents MASLD in ob/ob mice by modulating lipid metabolism and inflammation in the liver
by: Sergio López-Herrador, et al.
Published: (2025-09-01)

Outcomes of coronary revascularization in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review
by: Jacob J. Gries, et al.
Published: (2025-08-01)

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Ying Wang, et al.
Published: (2025-04-01)

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease
by: Yue Wang, et al.
Published: (2025-02-01)

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
by: Barbora Nováková, et al.
Published: (2025-08-01)

Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease
by: Susana Bernal, et al.
Published: (2025-07-01)

Association of dietary inflammatory index with liver fibrosis and fatty liver index in a population with metabolic dysfunction-associated steatotic liver disease: A cross-sectional study
by: Ziqi Sang, et al.
Published: (2025-06-01)

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
by: Bruno Basil, et al.
Published: (2024-12-01)

Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review
by: Vignesh Rajan, et al.
Published: (2025-07-01)

Hepatic stellate cell-specific Kcnma1 deletion mitigates metabolic dysfunction-associated steatotic liver disease progression via upregulating Amphiregulin secretion
by: Yunhan Zou, et al.
Published: (2025-07-01)

Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
by: Mohammad Alnees, et al.
Published: (2025-08-01)

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
by: Gina Ryu, et al.
Published: (2025-01-01)

An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease
by: Youngshim Choi, et al.
Published: (2025-06-01)

MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study
by: Shengbo Yang, et al.
Published: (2025-08-01)

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Nicholas A. Rouillard, et al.
Published: (2025-04-01)

Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults
by: Cheng Huang, et al.
Published: (2025-05-01)

Correction: An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease
by: Youngshim Choi, et al.
Published: (2025-06-01)

Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank
by: Qi Feng, et al.
Published: (2025-07-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy
by: Aleksander Jerzy Owczarek, et al.
Published: (2025-02-01)

Palmitic acid alters enhancers/super-enhancers near inflammatory and efferocytosis-associated genes in human monocytes
by: Vinay Singh Tanwar, et al.
Published: (2025-04-01)

Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus
by: Hilmi Erdem Sümbül, et al.
Published: (2025-03-01)

Akkermansia muciniphila ameliorates olanzapine-induced metabolic dysfunction-associated steatotic liver disease via PGRMC1/SIRT1/FOXO1 signaling pathway
by: Hui Chen, et al.
Published: (2025-03-01)

Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease
by: Eda Kaya, et al.
Published: (2025-01-01)

Dietary characteristics associated with the risk of non‐alcoholic fatty liver disease and metabolic dysfunction‐associated steatotic liver disease in non‐obese Japanese participants: A cross‐sectional study
by: Hirokazu Taniguchi, et al.
Published: (2024-05-01)

Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
by: Yang Yang, et al.
Published: (2025-07-01)

Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway
by: Johnny Amer, et al.
Published: (2025-06-01)

Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
by: Laiba Shakeel, et al.
Published: (2025-06-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
by: Vlad Alexandru Ionescu, et al.
Published: (2025-01-01)

Relationship between anthropometric measures and the risk of incident Metabolic dysfunction-associated steatotic liver disease: a longitudinal study
by: Takahiro Ichikawa, et al.
Published: (2025-03-01)

Green tea epigallocatechin gallate attenuate metabolic dysfunction-associated steatotic liver disease by regulation of pyroptosis
by: Jie Zhang, et al.
Published: (2025-05-01)